An alliance of Deerfield and the Broad Institute to accelerate research into high-mortality diseases identifies its first two research projects, while Janssen and UPenn look into gene therapy for Alzheimer's disease.
Below is Scrip’s monthly roundup, including information from Strategic Transactions, of recent technology transfer agreements between companies and academic or other research institutions.
Deerfield Management and the Broad Institute have selected their first two projects – one aimed at understanding and dealing with chemotherapy resistance in leukemia, and another investigating a genetic...
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.
The French drugmaker is expanding its neurology activities with the $470m deal.
